Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharmaceutical company reports first quarter financial results
August 15th, 2005
Mylan Laboratories Inc. (MYL) announced its financial results for the first quarter ended June 30, 2005. The company reported adjusted earnings per diluted share of $0.26 and GAAP earnings per diluted share of $0.16, which includes $0.03 for a contingent liability with respect to previously disclosed lorazepam and clorazepate product litigation. These results were at the high end of the preliminary ranges for adjusted and GAAP earnings per diluted share that were announced on July 11, 2005. Mylan had announced preliminary adjusted earnings per diluted share between $0.24 and $0.26 and GAAP earnings per diluted share between $0.14 and $0.16. ...
Source: Pharma Business Week (2005-08-15)
|
